

## Microba & Ginkgo Commence Therapeutics Program

- Microba announces commencement of its Autoimmune Disease program with Ginkgo Bioworks (NYSE: DNA)
- First strains from Microba's biobank delivered to Ginkgo
- Partnership brings together Microba's data-driven lead identification platform with Ginkgo's high throughput screening and Foundry capabilities to accelerate the development of novel therapies for autoimmune diseases
- Ginkgo invested US\$3.5m in Microba's IPO

**Microba Life Sciences Limited** (ASX: MAP) ("Microba" or the "Company") is pleased to announce that its Autoimmune Disease program has officially commenced, with the first strains from Microba's biobank supplied to development partner Ginkgo Bioworks ("Ginkgo").

Microba announced an agreement with Ginkgo (NYSE: DNA) in April 2022 to target the development of novel microbiome-based therapies for three autoimmune disorders: lupus, psoriatic arthritis and certain autoimmune liver diseases. Today's announcement that Microba has supplied the first strains for lead characterisation marks the start of activities to discover and develop novel microbiome-derived therapies.

**Microba's Chief Scientific Officer, Associate Professor Lutz Krause** said, "The partnership with Ginkgo will accelerate the identification of microbial therapeutic leads for autoimmune diseases and help us to select the most promising candidates, which is why we are very excited to commence this project."

The development partnership brings together Microba's proprietary, data-driven Therapeutic Platform with Ginkgo's automated screening capabilities at Ginkgo's Foundry facilities in Boston. This will enable Microba to leverage Ginkgo's high-throughput anaerobic culturing, multi-omics data collection and analysis, functional bioassay screening, and media and fermentation optimisation capabilities to generate datasets that characterise potential therapeutic strains targeting autoimmune disorders.

Ginkgo invested US\$3.5m in the Company's recent IPO on the Australian Securities Exchange (ASX).

*This announcement has been authorised for release by the Chairman and Chief Executive Officer.*

For further information, please contact:

**Dr Luke Reid**  
Chief Executive Officer  
E: [Luke.Reid@microba.com](mailto:Luke.Reid@microba.com)

**Simon Hinsley**  
Investor / Media Relations  
E: [simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au)  
T: +61 401 809 653

### **About Microba Life Sciences Limited**

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: [www.microba.com](http://www.microba.com)

### **About Ginkgo Bioworks**

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit [www.ginkgobioworks.com](http://www.ginkgobioworks.com)

**For more information visit: [www.microba.com](http://www.microba.com)**

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.